LINDIS Biotech Consolidates Onco-Immune, Trifunctional, Bispecific Antibody IP and Know-How from TRION Pharma
Horst Lindhofer, CEO of LINDIS Biotech and inventor of the trifunctional antibody technology succeeded in regaining the relevant IP and know-how from TRION Pharma out of the insolvency proceedings. Currently, LINDIS consolidates these patents and know-how with relevant LINDIS IP and hosts several advanced trifunctional antibody programs. The company plans to hire a limited number of highly experienced staff to continue clinical development once it has raised additional capital.
Dr Horst Lindhofer explained: “We seek to capitalise the company that now houses a pipeline of three new potential treatments against malignant tumours based on the trifunctional platform. One is in late pre-clinical and two are in Phase I/II clinical stage. The fund-raising comes at a great time given the compelling and positive clinical update of our Lymphomun programme.”
“When the industry converted to human/humanised antibodies, we chose to further develop our murine-based antibody platform due to its vaccination effect and the direct tumour-cell-killing potential that we discovered as early as 1997. Today we are unique because of this special characteristic. Our powerful effects on solid tumours were first verified in 2006,” explained Dr Lindhofer.
“We are grateful to our advisors, IMI Consulting GmbH (IMI) and Partners, for supporting us during the TRION Pharma insolvency process. IMI will now resume the discussions with potential investors for Round A,” Dr Lindhofer further added.
“The trifunctional antibody therapy is a platform that carries the hopes of cancer patients worldwide as it triggers the patient’s own immune system to recognise and destroy the cancer cells and, moreover, to induce a lasting immune memory against the individual mutations of the patient’s tumour cells. These antibodies can easily be adapted to fight many different types of cancers,” added Dr Lindhofer
Related News
-
News CPHI Frankfurt 2022: Innovator Interview – DSM Biomedical
At CPHI Frankfurt we spoke to Anne-Cecile Bayne, Global Science & Innovation Lead Pharma and Medical Nutrition, and Marc Hendriks, Vice President Strategy & Business Development, on their expertise in nitrosamines and business strategy at DSM Biomedica... -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled. -
News Magic mushrooms could be used to treat mental health conditions
A compound found in magic mushrooms, psilocybin, could be used to treat mental health conditions and help patients suffering with severe depression, as shown by the results of the largest study of its kind to date. -
News UK-based partnership to launch DETERMINE study into rare cancer research
UK-based CRO Quanticate is set to partner with Cancer Research UK for the launch of the DETERMINE study focused on testing a range of existing and approved drugs and therapies on rare cancers. -
News FDA approves Thermo Fisher blood tests for wheat and sesame allergies
Both tests have been approved by the US regulator for in vitro diagnostic use -
News QIAGEN launches world’s first syndromic test for monkeypox
The test can distinguish between monkeypox and other diseases that cause similar symptoms. -
News Monkeypox Update: Vaccine shortage, sewage surveillance and global testing
As concern over the monkeypox outbreak continues to rise, we take a look at major developments from the first week of August. -
News CPHI Podcast Series: The importance of novel excipients for innovative drug development
The latest episode in the CPHI Podcast Series dives into the world of novel excipients and explores their importance for innovative drug development.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance